Research Topics
| Ram YogevSummaryAffiliation: Northwestern University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infectionRam Yogev
Division of Infectious Diseases, Children s Memorial Hospital, Chicago, IL 60614 3394, USA
Pediatr Infect Dis J 21:119-25. 2002..Aim. To evaluate the safety, tolerance, antiviral activity and immunologic changes after the change to a three drug combination...
Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacyEllen Gould Chadwick
Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
Pediatr Infect Dis J 28:215-9. 2009....- Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapyEllen G Chadwick
Division of Infectious Diseases, Children s Memorial Hospital, Northwestern University s Feinberg School of Medicine, Chicago, Illinois, USA
AIDS 25:643-9. 2011..To investigate the longitudinal pharmacokinetics, safety and efficacy of lopinavir/ritonavir (LPV/r) in HIV-infected infants initiating combination antiretroviral therapy (cART) between 2 weeks and 6 months of age... - Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week resultsEllen G Chadwick
Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
AIDS 22:249-55. 2008..To investigate pharmacokinetics, safety and efficacy of lopinavir/ritonavir (LPV/r)-based therapy in HIV-1-infected infants 6 weeks to 6 months of age... - Management of brain abscesses in childrenRam Yogev
Children's Memorial Hospital, Chicago, IL, USA
Pediatr Infect Dis J 23:157-9. 2004 - Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of ageEllen Gould Chadwick
Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
Pediatr Infect Dis J 24:793-800. 2005..Few data are available regarding clinical outcomes or dosing requirements for the protease inhibitor ritonavir in human immunodeficiency virus (HIV)-infected children younger than under 24 months of age... 
Pharmacokinetics and distribution of linezolid in cerebrospinal fluid in children and adolescentsRam Yogev
Department of Pediatrics, Northwestern University Medical School, Chicago, IL, USA
Pediatr Infect Dis J 29:827-30. 2010..Two studies in hydrocephalic children and adolescents were performed to assess the penetration of linezolid into cerebrospinal fluid and its relation to meningeal inflammation...- Single-dose safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, in HIV-infected childrenRam Yogev
Division of Infectious Diseases, Children s Memorial Hospital, 2300 Children s Plaza, Box 155, Chicago, IL 60614, USA
Antimicrob Agents Chemother 49:336-41. 2005..Considerable interpatient variability was seen for all pharmacokinetic parameters of amprenavir. The results of this study suggest that 20 mg of amprenavir/kg administered twice a day should be used in future pediatric studies... - The role of protease inhibitor therapy in children with HIV infectionPatrick J Gavin
Division of Infectious Diseases, Children's Memorial Hospital and the Departments of Pediatrics, Northwestern University Medical School, Chicago, Illinois 60614-3394, USA
Paediatr Drugs 4:581-607. 2002..PI-containing HAART has transformed HIV infection into a chronic illness, and HIV-infected children now live longer... - Indirect protection of adults from rotavirus by pediatric rotavirus vaccinationEvan J Anderson
Departments of Pediatrics
Clin Infect Dis 56:755-60. 2013..Pediatric rotavirus vaccination correlated with a relative decline of almost 50% in rotavirus identified from adult BSC during the peak rotavirus season, suggesting that pediatric rotavirus vaccination protects adults from rotavirus... - Higher incidence of perineal community acquired MRSA infections among toddlersAlexis C McCullough
The University of Toledo College of Medicine, OH 43614, USA
BMC Pediatr 11:96. 2011..A six-fold increase in pediatric MRSA infections, prompted us to examine the clinical profile of children with MRSA infections seen at Mercy Children's Hospital, Toledo, Ohio and to characterize the responsible strains... - Bacterial meningitis in children: critical review of current conceptsRam Yogev
Feinberg School of Medicine, Children s Memorial Hospital, Chicago, Illinois 60614, USA
Drugs 65:1097-112. 2005.... - Neonatal sepsis caused by Streptococcus bovis variant (biotype II/2): report of a case and reviewPatrick J Gavin
Division of Infectious Diseases, Children s Memorial Hospital and Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
J Clin Microbiol 41:3433-5. 2003..bovis. We report a 3-day-old neonate with bacteremia and meningitis caused by S. bovis variant (S. bovis biotype II/2) and review the literature... - A rational approach to the management of ventricular shunt infectionsEvan J Anderson
Children's Memorial Hospital, Chicago, IL, USA
Pediatr Infect Dis J 24:557-8. 2005 - Linezolid for the treatment of complicated skin and skin structure infections in childrenRam Yogev
Children's Memorial Hospital, Chicago, IL, USA
Pediatr Infect Dis J 22:S172-7. 2003..CONCLUSIONS: Linezolid given iv or orally was well-tolerated and safe. It was as effective as vancomycin in treating children with Gram-positive CSSSIs... - Quantification of human immunodeficiency virus type 1 proviral DNA by using TaqMan technologyYuqi Zhao
Children s Memorial Institute for Education and Research, Northwestern University, Chicago, Illinois 60614, USA
J Clin Microbiol 40:675-8. 2002..Viral RNA levels, when at a stable state, were highly correlated with proviral DNA levels in 80 specimens of 18 HIV-infected children... - Differential gene expression of soluble CD8+ T-cell mediated suppression of HIV replication in three older childrenBen Z Katz
Department of Pediatrics, Northwestern University Feinberg School of Medicine and Children s Memorial Hospital, Chicago, Illinois 60614, USA
J Med Virol 83:24-32. 2011..Our data also lends some support to the recent identification of CAF with exosomes secreted by CD8+ T-cells... - Mycobacterium gordonae bacteremia in an asymptomatic adolescent with acquired immunodeficiency syndromeRobert Garofalo
Division of Infectious Diseases, Children's Memorial Hospital, Chicago, IL, USA
Pediatr Infect Dis J 22:569-70. 2003..Illness related to M. gordonae infection ranges from localized infections to rare cases of disseminated disease. This report describes treatment of the first case of occult M. gordonae bacteremia in an adolescent with AIDS... - Recombinant glycoprotein vaccines for human immunodeficiency virus-infected children and their effects on viral quasispeciesShaffiq M Essajee
Department of Pediatrics, Division of Infectious Diseases, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
Clin Diagn Lab Immunol 9:79-82. 2002..These results suggest that the immune response elicited by RGP vaccines does not exert a significant selection pressure on the viral quasispecies and therefore may not be helpful in changing the course of the disease... - Evaluation of multiple drug therapy in human immunodeficiency virus-infected pediatric patientsJennifer R King
Division of Clinical Pharmacology, University of Alabama at Birmingham, 35294, USA
Pediatr Infect Dis J 22:239-44. 2003..Larger controlled clinical trials in this patient population are necessary to determine whether the benefit of this therapeutic approach outweighs potential risks... - Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021Ross E McKinney
Department of Pediatrics, Duke University Medical Center, Box 3461, Durham, NC 27710, USA
Pediatrics 120:e416-23. 2007..Compliance with complex antiretroviral therapy regimens is a problem for HIV-1-infected children and their families. Simple, safe, and effective regimens are important for long-term therapeutic success... - Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infectionCourtney V Fletcher
Pediatric AIDS Clinical Trials Group and the Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver 80262, USA
Pharmacotherapy 24:453-9. 2004..To evaluate and describe the parameters and characteristics of different drug regimens in children infected with human immunodeficiency virus (HIV)... - Long-term safety and efficacy results of once-daily emtricitabine-based highly active antiretroviral therapy regimens in human immunodeficiency virus-infected pediatric subjectsXavier Saez-Llorens
Infectious Disease Department, Hospital del Nino, Panama City, Panama
Pediatrics 121:e827-35. 2008.... - Structured treatment interruptions (STIs) in HIV-1 infected pediatric populations increases interferon gamma production and reduces viremiaWilliam Borkowsky
NYU School of Medicine, New York, NY, USA
Vaccine 26:3086-9. 2008..This allowed us to conclude that exposure to autologous virus increased HIV-specific immune responses and decreased HIV RNA were seen in those who have had >13 interruptions, with STI intervals that exceeded 27 days... - Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitorsBrian L Robbins
St Jude Children s Research Hospital, Memphis, Tennessee, USA
Antimicrob Agents Chemother 52:3276-83. 2008.... - Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescentsJuan C Salazar
Connecticut Children s Medical Center, University of Connecticut School of Medicine, Hartford, Connecticut 06106, USA
AIDS 22:1789-98. 2008..To evaluate the efficacy, safety and tolerability of ritonavir-boosted tipranavir (TPV/r) in HIV-1-infected pediatric patients... - Growth in human immunodeficiency virus-infected children receiving ritonavir-containing antiretroviral therapySharon A Nachman
Department of Pediatrics, State University of New York Health Science Center at Stony Brook, Stony Brook, NY 11794 8111, USA
Arch Pediatr Adolesc Med 156:497-503. 2002..Human immunodeficiency virus (HIV)-infected children often suffer from impaired growth. Highly active antiretroviral therapy (HAART) successfully reduces HIV 1 (HIV-1) RNA to 400 copies/mL or less in many children... - Virologic response to potent antiretroviral therapy and modeling of HIV dynamics in early pediatric infectionPaul Palumbo
Department of Pediatrics, University of Medicine and Dentistry New Jersey Medical School, Newark, NJ, USA
J Infect Dis 196:23-9. 2007..Similar studies are needed in pediatric populations, in whom differing dynamics might translate into age-specific treatment approaches... - Planned multiple exposures to autologous virus in HIV type 1-infected pediatric populations increases HIV-specific immunity and reduces HIV viremiaWilliam Borkowsky
NYU School of Medicine, New York, New York 10016, USA
AIDS Res Hum Retroviruses 24:401-11. 2008..Other studies may have failed due to an insufficient number of exposures to HIV; most of the studies had fewer than six drug interruptions... - Rapid human immunodeficiency virus decay in highly active antiretroviral therapy (HAART)-experienced children after starting mega-HAARTNottasorn Plipat
Division of Infectious Diseases, Department of Pediatrics, Siriraj Hospital, Mahidol University, Bangkok, Thailand
J Virol 78:11272-5. 2004..026d(-1), range = -0.005 to 0.206, t2(1/2) = 9.316d). This indicates that mega-HAART can provide potent therapy among heavily experienced pediatric patients... - Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected childrenRita J Jeremy
Pediatric Clinical Research Center, Department of Pediatrics, School of Medicine, University of California San Francisco, 505 Parnassus Ave, San Francisco, CA 94143 0105, USA
Pediatrics 115:380-7. 2005..Neuropsychological functioning and its correlation with viral load were investigated for previously treated HIV-infected children who underwent a change in treatment regimen... - Switch from ritonavir to indinavir in combination therapy for HIV-1-infected childrenStephen I Pelton
Boston Medical Center, Boston, MA 02118, USA
Clin Infect Dis 40:1181-7. 2005.... - Balancing the upside and downside of antiretroviral therapy in childrenRam Yogev
JAMA 293:2272-4. 2005 - Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403Jennifer R King
University of Alabama at Birmingham, Birmingham, USA
Pediatr Infect Dis J 24:880-5. 2005..Differences in tolerability between the 2 treatment groups were not identified. Systemic exposure of these drugs was similar to that reported in other HIV-infected children and adults... - Linezolid versus vancomycin for treatment of resistant Gram-positive infections in childrenSheldon L Kaplan
Baylor College of Medicine and Texas Children s Hospital, 6621 Fannin Street, MC3 2371, Feigin Center No 1150, Houston, TX 77030, USA
Pediatr Infect Dis J 22:677-86. 2003..Pediatric infections caused by resistant Gram-positive infections are an increasing concern with limited treatment options. Linezolid, a new oxazolidinone, is active against staphylococci, streptococci and enterococci... - A behavioral and cognitive profile of clinically stable HIV-infected childrenMolly L Nozyce
Department of Pediatrics, Bronx Lebanon Hospital Center, Bronx, New York, USA
Pediatrics 117:763-70. 2006..The purpose of this research was to characterize behavioral and cognitive profiles of clinically and immunologically stable antiretroviral-experienced HIV-infected children... - Pharmacokinetics of antiretrovirals administered to HIV-infected children via gastrostomy tubeJennifer R King
Division of Clinical Pharmacology, University of Alabama at Birmingham, 1530 3rd Avenue South, Birmingham, AL 35294, USA
HIV Clin Trials 5:288-93. 2004..CONCLUSION: This pilot study suggests that administration of most PIs and NNRTIs by a g-tube to HIV-infected children provides systemic exposure comparable with that achieved after oral administration... - Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infectionWalter T Hughes
Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
Clin Infect Dis 40:136-45. 2005.... - Single-dose pharmacokinetics of enteric-coated didanosine in HIV-infected childrenJennifer R King
The University of Alabama at Birmingham, Birmingham, Ala, USA
Antivir Ther 7:267-70. 2002.... - Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapyAdriana Weinberg
Department of Pediatrics and Medicine, University of Colorado Health Sciences Center, Denver, Colorado, USA
J Infect Dis 193:302-11. 2006..We investigated the safety and immunogenicity of 2 doses of hepatitis A virus (HAV) vaccine followed by a booster dose in HIV-infected children receiving stable highly active antiretroviral therapy... - The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxisSharon Nachman
Department of Pediatrics, Stony Brook University, Stony Brook, NY 11794 8111, USA
Pediatrics 115:e488-94. 2005.... - Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of ageTerry Nolan
School of Population Health, University of Melbourne and Murdoch Children s Research Institute, Carlton, Melbourne, Victoria 3010, Australia
Pediatrics 121:508-16. 2008..This study evaluated the safety, tolerability, and immunogenicity of live attenuated influenza vaccine administered concurrently with measles-mumps-rubella vaccine and varicella vaccine to healthy children 12 to 15 months of age... - Opportunities to prevent HIV transmission in newbornsRam Yogev
Pediatrics 118:436-7; author reply 437. 2006